Senate confirmation of Heidi Overton as FDA commissioner faces hurdles tied to Republican divisions on vaccines and the abortion drug mifepristone. Nominated by President Trump in August 2026 after the resignation of prior commissioner Marty Makary, Overton serves as deputy director of the White House Domestic Policy Council and appeared at the September 24 HELP Committee hearing. Chairman Sen. Bill Cassidy and Sen. Josh Hawley have raised concerns over her managerial experience, participation in a childhood vaccine schedule executive order, and willingness to maintain agency independence on mifepristone safety reviews. With a narrow GOP Senate majority and HELP committee split of 12 Republicans to 11 Democrats, any defections could delay or block advancement amid a tight legislative calendar. Traders weigh these procedural and policy frictions against administration support for swift action.